News

Ono Pharmaceutical Co., Ltd. announced that it has entered into a research collaboration agreement with Jorna Therapeutics in December 2024 aimed at drug discovery using Jorna's…
Read More...

Roche announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US…
Read More...

uniQure N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare,…
Read More...

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a…
Read More...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU)…
Read More...

BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collaboration with Eli…
Read More...

Cellino, a biotechnology company pioneering autonomous biomanufacturing for personalized regenerative medicine, announced its expansion into the Asia-Pacific region through a strategic…
Read More...

Boehringer Ingelheim and Cue Biopharma, Inc. announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a…
Read More...

Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed…
Read More...

Pfizer Inc. announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for…
Read More...

REVEAL GENOMICS and Ona Therapeutics announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the…
Read More...

Ironwood Pharmaceuticals, Inc., a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced…
Read More...

Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class…
Read More...

Valneva SE, a specialty vaccine company announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ for the…
Read More...

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Biopharmaceutical company Cingulate Inc. has been awarded a $3 million grant from a private foundation to accelerate the development of its once-daily anxiety treatment, CTx-2103…
Read More...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has received approval from the U.S. Food and Drug Administration (FDA) for its cancer treatment biosimilar, Jobevne…
Read More...

The U.S. Food and Drug Administration (FDA) has announced a significant shift in drug development, aiming to replace animal testing with more effective, human-relevant methods. This…
Read More...

Renovaro Biosciences Inc., a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, announced it closed its previously…
Read More...

Epsilogen announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company developing engineered immunoglobulin A (IgA) antibodies, to create the world’s leading…
Read More...